016 Life After Transplant: Maintenance Treatment in Myeloma Care скачать в хорошем качестве

016 Life After Transplant: Maintenance Treatment in Myeloma Care

Welcome to The Myeloma Minutes.  We've now moved to a fortnightly release schedule, so you can now hear us every-other Thursday. This episode explores what happens after a stem cell transplant in multiple myeloma, focusing on consolidation and maintenance treatments - especially the use of lenalidomide - and how these therapies aim to sustain remission and quality of life. 📌Key Takeaways: • Maintenance therapy isn't just more treatment - it's your path to a longer, better-quality remission. • Side effects like diarrhoea and cramps are common - but manageable, and shouldn't be suffered in silence. • A future with shorter or even time-limited maintenance might be closer than you think. This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns   ABOUT YOUR HOSTS Dr. Jam Kothari Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.   Dr. Sally Moore Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.